TAMPA, Fla.--(BUSINESS WIRE)--As Neutra Corp. (OTCBB: NTRR) and its partners continue to make inroads into the booming Colorado cannabis market, the latest industry sales figures have set a new record high for the third month in a row.
Roughly $74 million worth of legal cannabis was sold in Colorado in March, according to numbers reported last month by thejointblog.com and calculated using tax data released by the Colorado Department of Revenue. Consumers spent more than $42 million on adult-use cannabis and $32 million on medicinal cannabis. $74 million set a new monthly sales record for the state for the third month straight.
“The continued growth of this industry has been both totally amazing and fully expected,” said NTRR CEO Chris Brown. “We believe that the cannabis market in Colorado will crack $1 billion this year, and we’re working very enthusiastically to make our company a vital part of this emerging economy.”
Alongside its joint venture partner, Surface to Air Solutions, Inc. (S2O2), NTRR is working to deliver a powerful new suite of horticultural weapons to Colorado growers and retailers in the fight against cannabis contamination from mold, pesticides and other potentially harmful irritants. Last week, NTRR announced that the company signed a letter of intent with Colorado plant specialists Green Mountain Plant Health, LLC, to supply this line of antimicrobial products for the healthy treatment of industrial cannabis crops and other indoor agricultural projects to its clients.
NTRR is committed to providing breakthrough products and services to the Colorado cannabis market, where one of the nation’s fastest-growing industries continues to thrive.
About Neutra Corp.
Neutra Corp. is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products. By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (OTCBB: GWPRF), INSYS Therapeutics, Inc. (NASDAQ: INSY) and ENDEXX Corp. (OTCBB: EDXC), delivering technological advancements in the cultivation and processing of cannabis in approved markets. For investing information and performance data, please visit www.neutracorp.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
